Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

In silico prediction of optimal multifactorial intervention in CKD

View ORCID ProfileAgnieszka Latosinska, View ORCID ProfileIoanna K Mina, Thi Minh Nghia Nguyen, Igor Golovko, Felix Keller, Gert Mayer, View ORCID ProfilePeter Rossing, View ORCID ProfileJan A Staessen, View ORCID ProfileChristian Delles, View ORCID ProfileJoachim Beige, View ORCID ProfileGriet Glorieux, Andrew L Clark, View ORCID ProfileJoost P Schanstra, View ORCID ProfileAntonia Vlahou, View ORCID ProfileKarlheinz Peter, View ORCID ProfileIvan Rychlík, Alberto Ortiz, View ORCID ProfileArchie Campbell, View ORCID ProfileHarald Rupprecht, View ORCID ProfileFrederik Persson, View ORCID ProfileHarald Mischak, View ORCID ProfileJustyna Siwy
doi: https://doi.org/10.1101/2025.02.14.25322292
Agnieszka Latosinska
1Mosaiques Diagnostics GmbH, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Agnieszka Latosinska
Ioanna K Mina
1Mosaiques Diagnostics GmbH, Hannover, Germany
2Institute for Molecular Cardiovascular Research, University Hospital RWTH Aachen, Aachen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ioanna K Mina
Thi Minh Nghia Nguyen
1Mosaiques Diagnostics GmbH, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Igor Golovko
1Mosaiques Diagnostics GmbH, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felix Keller
3Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gert Mayer
3Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Rossing
4Steno Diabetes Center Copenhagen, Herlev, Denmark
5Department of Clinical Medicine, University of Copenhagen, Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter Rossing
Jan A Staessen
6Non-Profit Research Institute Alliance for the Promotion of Preventive Medicine, Mechlin, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jan A Staessen
Christian Delles
7School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian Delles
Joachim Beige
8Division of Nephrology and KfH Renal Unit, Hospital St Georg, Leipzig, Germany; Martin-Luther University Halle, Wittenberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joachim Beige
Griet Glorieux
9Nephrology Section, Department of Internal Medicine and Paediatrics, Ghent University Hospital, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Griet Glorieux
Andrew L Clark
10Hull and East Yorkshire NHS Hospitals Trust, Castle Hill Hospital, Cottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joost P Schanstra
11Institut National de la Santé et de la Recherche Médicale (INSERM), U1297, Institute of Cardiovascular and Metabolic Disease, Toulouse, France
12Université Toulouse III Paul-Sabatier, Route de Narbonne, Toulouse, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joost P Schanstra
Antonia Vlahou
13Centre of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antonia Vlahou
Karlheinz Peter
14Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
15Department of Physiology, Anatomy, Microbiology, La Trobe University, Melbourne, VIC, Australia
16Department of Medicine and Immunology, Monash University, Melbourne, VIC, Australia
17Department of Cardiometabolic Health, University of Melbourne, VIC, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karlheinz Peter
Ivan Rychlík
18Department of Internal Medicine, Third Faculty of Medicine, Charles University, and University Hospital Královské Vinohrady, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ivan Rychlík
Alberto Ortiz
19Instituto de investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD) UAM, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Archie Campbell
20Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Archie Campbell
Harald Rupprecht
21Department of Nephrology, Angiology and Rheumatology, Klinikum Bayreuth GmbH, Bayreuth, Germany
22Department of Nephrology, Medizincampus Oberfranken, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
23Kuratorium for Dialysis and Transplantation (KfH) Bayreuth, Bayreuth, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harald Rupprecht
Frederik Persson
5Department of Clinical Medicine, University of Copenhagen, Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Frederik Persson
Harald Mischak
1Mosaiques Diagnostics GmbH, Hannover, Germany
7School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harald Mischak
Justyna Siwy
1Mosaiques Diagnostics GmbH, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Justyna Siwy
  • For correspondence: siwy{at}mosaiques-diagnostics.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background and Aims Chronic kidney disease (CKD) significantly contributes to global morbidity and mortality. Early, targeted intervention offers an ideal strategy for mitigating this burden. Peptidomic changes inform on CKD onset and progression and hold insights for treatment strategies. We investigated the molecular effects of six different therapeutic interventions in silico in all possible combinations on the urine peptidome, aiming to identify the most beneficial treatment for individual patients.

Method This study predicted major adverse kidney events (MAKE), defined as a ≥40% decline in estimated glomerular filtration rate (eGFR) or kidney failure (median follow up time of 1.50 (95%CI 0.35, 5.0)), using the urinary peptidomic classifier CKD273 in a retrospective cohort of 935 participants. The impact of various treatments on urinary peptidomic profiles, assessed from previous studies of four different drug-based interventions (MRA, SGLT2i, GLP1-RA and ARB), one dietary intervention (olive oil) or from exercise, was applied. Treatment effects were quantified through fold changes in peptide abundance after treatment, recalibrated to align with outcomes observed in randomized controlled trials and applied to patient-specific urinary profiles, simulating intervention effects and recalculation of CKD273 scores for each individual. For combination treatments, the effects of multiple interventions were combined to model their cumulative impact.

Results Simulated interventions demonstrated a significant reduction in median CKD273 scores, from 0.57 (IQR: 0.19–0.81) before to 0.039 (IQR: -0.192–0.363) after intervention (paired Wilcoxon test, P < 0.0001), when the most beneficial treatment or combination of treatments was applied individually. The combination of all available treatments was found optimal only for 17.6% of the patients and not the most frequently predicted optimal intervention. Patients with higher baseline CKD273 scores required more complex intervention combinations to achieve the greatest reduction in scores. The findings present potential individualized treatment strategies in CKD management.

Conclusion This study supports the feasibility of in silico predicting effects of therapeutic interventions on CKD progression. By identifying the most beneficial treatment combinations for individual patients, this approach paves the way for precision medicine in CKD.

Graphical abstract:
  • Download figure
  • Open in new tab
Graphical abstract:

Urinary peptidomics data from different types of intervention were applied in silico to predict the impact of treatment, with the extent of the impact being calibrated to fit the observed effect in large randomized trials. The personalized optimal combination of interventions was determined in 935 patients, based on the impact on CKD273. The results indicate that guiding personalized treatment based on urine peptide data is possible and may substantially improve patient management.

Competing Interest Statement

Conflicts of Interest: HM is the founder and co-owner of Mosaiques Diagnostics (Hannover, Germany). AL, TMNN, IG, IM and AL are employed by Mosaiques Diagnostics. PR has received grants from Astra Zeneca. Bayer and Novo Nordisk and honoraria (to Steno Diabetes Center Copenhagen) from Astra Zeneca. Abbott. Bayer. Boehringer Ingelheim. Eli Lilly. Novo Nordisk. Gilead. and Sanofi. AO has received grants from Sanofi and consultancy or speaker fees or travel support from Adviccene. Alexion. Astellas. Astrazeneca. Amicus. Amgen. Boehringer Ingelheim. Fresenius Medical Care. GSK. Bayer. Sanofi-Genzyme. Menarini. Mundipharma. Kyowa Kirin. Lilly. Freeline. Idorsia. Chiesi. Otsuka. Novo-Nordisk. Sysmex and Vifor Fresenius Medical Care Renal Pharma and is Director of the Catedra UAM-Astrazeneca of chronic kidney disease and electrolytes. He has stock in Telara Farma. F.P. has served as a consultant on advisory boards or as an educator for Astra Zeneca, Novo Nordisk, Sanofi, Mundipharma, MSD, Boehringer Ingelheim, Novartis, and Amgen, and has received research grants to institution from Novo Nordisk, Amgen, and Astra Zeneca. All other authors have no potential conflicts of interest.

Funding Statement

This project was supported in part by the German ministry for education and science (BMBF) via UPTAKE (01EK2105A 01EK2105B) to HM JS and AL. Additional funding was provided by the ERA PerMed SIGNAL project (01KU2307) Accurate-CVD (ZIM KK5560002AP3) funded by the by the BMWK (Federal Ministry for Economic Affairs and Climate Protection), European Union Horizon 2020 research and innovation programme under grant agreement No 848011 for the DC-ren project and the European Union Horizon Europe Marie Skłodowska Curie Actions Doctoral Networks Industrial Doctorates Programme DisCo-1 (HORIZON MSCA 2021 DN, 101072828) and PICKED (HORIZON MSCA 2023 DN, 101168626). AO research is supported by FIS/Fondos FEDER ERA PerMed JTC2022 (SPAREKID AC22/00027). Comunidad de Madrid en Biomedicina P2022/BMD 7223. CIFRA COR CM. Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union NextGenerationEU. Mecanismo para la Recuperacion y la Resiliencia (MRR) and SPACKDc PMP21/00109. FEDER funds. The project also received support from the COST Action PERMEDIK CA21165. supported by COST (European Cooperation in Science and Technology) and from the PREVENTCKD Consortium. Project ID: 101101220 Programme: EU4H. DG/Agency: HADEA. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the granting authorities. Neither the European Union nor the granting authority can be held responsible for them.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used ONLY openly available human data that were originally published in Pharmaceuticals (Basel). 2023 Sep 14;16(9):1298. doi: 10.3390/ph16091298.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted February 18, 2025.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
In silico prediction of optimal multifactorial intervention in CKD
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In silico prediction of optimal multifactorial intervention in CKD
Agnieszka Latosinska, Ioanna K Mina, Thi Minh Nghia Nguyen, Igor Golovko, Felix Keller, Gert Mayer, Peter Rossing, Jan A Staessen, Christian Delles, Joachim Beige, Griet Glorieux, Andrew L Clark, Joost P Schanstra, Antonia Vlahou, Karlheinz Peter, Ivan Rychlík, Alberto Ortiz, Archie Campbell, Harald Rupprecht, Frederik Persson, Harald Mischak, Justyna Siwy
medRxiv 2025.02.14.25322292; doi: https://doi.org/10.1101/2025.02.14.25322292
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
In silico prediction of optimal multifactorial intervention in CKD
Agnieszka Latosinska, Ioanna K Mina, Thi Minh Nghia Nguyen, Igor Golovko, Felix Keller, Gert Mayer, Peter Rossing, Jan A Staessen, Christian Delles, Joachim Beige, Griet Glorieux, Andrew L Clark, Joost P Schanstra, Antonia Vlahou, Karlheinz Peter, Ivan Rychlík, Alberto Ortiz, Archie Campbell, Harald Rupprecht, Frederik Persson, Harald Mischak, Justyna Siwy
medRxiv 2025.02.14.25322292; doi: https://doi.org/10.1101/2025.02.14.25322292

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Nephrology
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3298)
  • Dentistry and Oral Medicine (365)
  • Dermatology (280)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1173)
  • Epidemiology (13384)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5157)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3274)
  • Health Policy (1143)
  • Health Systems and Quality Improvement (1193)
  • Hematology (432)
  • HIV/AIDS (1019)
  • Infectious Diseases (except HIV/AIDS) (14636)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (478)
  • Medical Ethics (127)
  • Nephrology (525)
  • Neurology (4930)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (886)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (727)
  • Orthopedics (282)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (544)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4218)
  • Public and Global Health (7511)
  • Radiology and Imaging (1708)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (424)
  • Surgery (549)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)